Zelgen(SH:688266) 智通财经网·2025-09-11 07:56Core Insights - The company Zai Lab (stock code: 688266.SH) announced that clinical research data and updates for its self-developed drugs Alveltamig (code: ZG006) and Nilvanstomig (code: ZG005) will be presented at the 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) from September 10 to 14, 2025 [1] Group 1: ZG006 Clinical Research - ZG006 is undergoing a Phase II dose-optimization clinical study (ZG006-002) for the treatment of refractory advanced small cell lung cancer (SCLC) patients, which has been selected for an oral presentation at the conference [1] - As of May 12, 2025, a total of 60 SCLC patients who have undergone three or more lines of treatment were randomly assigned to receive either ZG006 at 10mg Q2W or 30mg Q2W, with the initial dose being 1mg [1] - The baseline characteristics of both patient groups were generally balanced [1] Group 2: ZG005 Clinical Research - ZG005 is being evaluated in a Phase I/II clinical study (ZG005-004) for its safety, pharmacokinetics, and preliminary efficacy in combination with Etoposide and Cisplatin (EP) for first-line treatment of advanced neuroendocrine carcinoma [1] - As of August 21, 2025, a total of 84 patients have been enrolled in the study, with 92.9% of patients having a Ki-67 proliferation index of ≥55% and 64.3% of patients exhibiting liver metastasis [1] - The most common primary tumor site among patients was the gastrointestinal tract, accounting for 36.9% [1]